BMS 986231

Drug Profile

BMS 986231

Alternative Names: BMS-986231; CXL 1427

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator Cardioxyl Pharmaceuticals
  • Developer Bristol-Myers Squibb
  • Class Heart failure therapies
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute heart failure

Most Recent Events

  • 09 Jan 2017 Bristol-Myers Squibb plans the phase IIb STANDUP AHF trial for Acute heart failure in USA, United Kingdom, Argentina, Canada, Czech Republic, France, Germany, Greece, Italy, Netherlands, Poland and Spain (IV, infusion) (NCT03016325)
  • 12 Oct 2016 Bristol-Myers Squibb plans a phase I trial in Healthy volunteers in USA (IV) (NCT02932969)
  • 08 Dec 2015 Cardioxyl Pharmaceuticals has been acquired and merged into Bristol-Myers Squibb
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top